In conclusion, the present study reveals, for the first time, that damaged mitochondria of uremic patients through an elevated production of ROS could be able to activate NLRP3 inflammasome representing a new deregulated biological machinery and a novel therapeutic target in CKD-HD patients. Here, NLRP3 is linked to Huntington disease.